Alzeca Biosciences
Biotechnology, 1800 Bering Dr, Houston, Texas, 77057, United States, 1-10 Employees
Phone Number: +16*********
Who is ALZECA BIOSCIENCES
Alzheimers affects approximately 5.5 million Americans and is projected to quadruple by 2050. It is the 6th leading cause of death. Early detection of Alzheimers is critical as disease pa...
Read More
- Headquarters: 1800 Bering Dr, Houston, Texas, 77057, United States
- Date Founded: 2012
- Employees: 1-10
- Revenue: Under $1 Million
- Active Tech Stack: See technologies
- CEO: Carlo Medici
Industry: Biotechnology
SIC Code: 8731
Does something look wrong? Fix it. | View contact records from ALZECA BIOSCIENCES
Alzeca Biosciences Org Chart and Mapping
Similar Companies to Alzeca Biosciences
Iterion Therapeutics
- 11-50
- $ 1 Million to 5 Million
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Alzeca Biosciences
Answer: Alzeca Biosciences's headquarters are located at 1800 Bering Dr, Houston, Texas, 77057, United States
Answer: Alzeca Biosciences's phone number is +16*********
Answer: Alzeca Biosciences's official website is https://alzeca.com
Answer: Alzeca Biosciences's revenue is Under $1 Million
Answer: Alzeca Biosciences's SIC: 8731
Answer: Alzeca Biosciences has 1-10 employees
Answer: Alzeca Biosciences is in Biotechnology
Answer: Alzeca Biosciences top competitors include: Iterion Therapeutics
Answer: Alzeca Biosciences contact info: Phone number: +16********* Website: https://alzeca.com
Answer: Alzheimers affects approximately 5.5 million Americans and is projected to quadruple by 2050. It is the 6th leading cause of death. Early detection of Alzheimers is critical as disease pathology begins to accumulate 10-15 years prior to the cognitive onset of the disease. As a result, early detection of Alzheimers pathology offers patients an opportunity to take counteractive measures at a point where the disease is far more treatable. Alzeca Biosciences mission is to develop best in class imaging technologies for the early detection of Alzheimers Disease pathology. Alzecas imaging technologies will be applied to offer 1) Improved patient selection and monitoring of Alzheimers patients in clinical trials, and 2) Differential Diagnosis of patients with MCI (Mild Cognitive Impairment). To date, Alzeca has been supported by private investors and grants to its academic partners from the Cure Alzheimers Fund, Alzheimers Association, NIH, and Alliance for NanoHealth. Alzecas co-founders have more than 25 years of experience in drug development and the company features several renowned Key Opinion Leaders on the Scientific Advisory Board.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Sign in to CIENCE GO Data to uncover contact details
Free credits every month